Ardelyx (ARDX) Return on Capital Employed (2014 - 2026)
Ardelyx (ARDX) reported Return on Capital Employed of 9.51% for Q1 2026, up 190.0% on a YoY basis from 3.28% in Q1 2025, and up 5.94% quarter-over-quarter from 10.11% in Q4 2025.
Ardelyx (ARDX) Return on Capital Employed (2014 - 2026) Analysis & Trends
Ardelyx has reported Return on Capital Employed for 13 years, with the latest figure at 9.51% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 190.0% year-over-year to 9.51%; the trailing twelve-month figure through Mar 2026 stood at 9.51% (up 190.0% YoY), and the FY2025 full-year result was 10.78%, down 110.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 9.51%, up from 10.11% in the prior quarter.
- The five-year high for Return on Capital Employed was 8.63% in Q4 2024, with the low at 163.53% in Q1 2022.
- Historically, Return on Capital Employed has averaged 44.67% across 5 years, with a median of 22.46% in 2024.
- Annual changes were most pronounced in 2022 — Return on Capital Employed slumped 10199 bps — and 2023, when it soared 12638 bps.
- Ardelyx's Return on Capital Employed stood at 62.65% in 2022, then jumped by 58 bps to 26.03% in 2023, then surged by 67 bps to 8.63% in 2024, then declined by 17 bps to 10.11% in 2025, then gained by 6 bps to 9.51% in 2026.
- The last three Return on Capital Employed figures came in at 9.51% (Q1 2026), 10.11% (Q4 2025), and 9.65% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Ardelyx | 1.49 Bn | 1.25 Bn | 89.66 Mn | -9.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.51% |
| Dec 31, 2025 | -10.11% |
| Sep 30, 2025 | -9.65% |
| Jun 30, 2025 | -11.32% |
| Mar 31, 2025 | -11.41% |
| Dec 31, 2024 | -8.63% |
| Sep 30, 2024 | -22.46% |
| Jun 30, 2024 | -21.00% |
| Mar 31, 2024 | -23.52% |
| Dec 31, 2023 | -26.03% |
| Sep 30, 2023 | -11.19% |
| Jun 30, 2023 | -34.39% |
| Mar 31, 2023 | -44.15% |
| Dec 31, 2022 | -62.65% |
| Sep 30, 2022 | -128.99% |
| Jun 30, 2022 | -160.78% |
| Mar 31, 2022 | -163.53% |
| Dec 31, 2021 | -143.50% |
| Sep 30, 2021 | -123.14% |
| Jun 30, 2021 | -81.17% |